Project Grant R01MH139612
Award Date 8/24/26
Completion Date 5/31/31
Dollars Obligated $724K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45229, USA
Similar Awards
- The National Institute of Mental Health awarded The Children's Hospital Corporation (Boston Children's Hospital) $497,364 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to support research on therapeutic targeting of proteostasis in Fragile X Syndrome. The work investigates protein degradation mechanisms in Fragile X Syndrome and tests proteasome inhibition as a novel therapeutic strategy. The research interrogates whether increased ubiquitin proteasome system...
- The National Institute of Child Health and Human Development awarded Cincinnati Children's Hospital Medical Center $445,500 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop and test genetic and molecular assays for predicting disease severity in Fragile X Syndrome. The research addresses the absence of early quantitative biomarkers that currently prevent individualized therapeutic strategies for FXS patients. The project...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Cincinnati Children's Hospital Medical Center a $900,000 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) on September 18, 2025, with an ultimate completion date of August 31, 2030. This mechanistic and translational medicine research initiative addresses critical knowledge gaps in Fragile X Syndrome (FXS) by establishing...
- The National Institute of Mental Health awarded Emory University $430,375 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct spatial translational dysregulation research in Fragile X Syndrome. The award funds construction of high-resolution, single-cell maps of translational regulation in Fragile X Syndrome mouse brains using advanced spatial genomics technologies including STARMAP-PLUS and RIBOMAP. Research aims include generating spatial transcriptomics...
- The National Institute of Mental Health awarded The Leland Stanford Junior University $739,125 for a project grant to decipher the molecular function of fragile X messenger ribonucleoprotein (FMRP) in fragile X syndrome, awarded on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242). The project investigates FMRP's role in translational regulation and its relationship to fragile X syndrome pathogenesis. Fragile X syndrome, the most prevalent form of inherited...
- The National Institute of Child Health and Human Development awarded $429,000 to The Regents Of The University Of Colorado (University of Colorado-Denver) on August 14, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to characterize Fragile X Syndrome in the human brain using post-mortem human tissue. The research team will study cell-type-specific gene expression in Fragile X Syndrome human brain tissue and investigate length and methylation...
- The National Institute of Mental Health awarded The General Hospital Corporation (Massachusetts General Hospital) $824,998 under Project Grant R01MH137056 on June 1, 2026, to investigate r-loop-induced CGG contraction as a therapeutic approach for Fragile X Syndrome. The funded research examines how two compounds—a MEK inhibitor and a BRAF inhibitor—reactivate the silenced FMR1 gene by promoting DNA demethylation and forming site-specific r-loops that recruit endogenous DNA repair mechanisms...
- The National Institute of Neurological Disorders and Stroke, a component of the Department of Health and Human Services National Institutes of Health, awarded $445,500 to Cincinnati Children's Hospital Medical Center on July 25, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to conduct preclinical research on microRNA-mediated regulation of IL-17A-associated neurodevelopmental defects induced by maternal immune activation. The...
- The National Institute of Mental Health awarded Yale University $157,388 on July 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to functionally characterize somatic mosaic variants in the brains of patients with schizophrenia and autism and determine their causal roles in neurodevelopmental disease. The funded work applies massively parallel reporter assays, CRISPR technology, and human induced pluripotent stem cell-derived neural progenitor cells and post-mitotic neurons...
- The National Institute of Mental Health awarded Michigan State University $416,859 on March 3, 2026, under the Mental Health Research Grants program (CFDA 93.242) to probe nucleolus function in a mouse model of Fragile X Syndrome. The research aims to explore nucleolar hyper-function as a novel aspect of FXS pathology. The investigator proposes that this hyper-function drives aberrant ribosome biogenesis, thereby increasing cellular translation capacity and explaining the elevated global protein...